Browsing ICR Divisions by title
Now showing items 4460-4479 of 4595
-
Unraveling Desmoid-Type Fibromatosis-Specific Health-Related Quality of Life: Who Is at Risk for Poor Outcomes.
(MDPI, 2022-06-16)Desmoid-type fibromatosis (DTF) is a rare, soft-tissue tumour. These tumours do not metastasize, but their local aggressive tumour growth and unpredictable behaviour can have a significant impact on health-related quality ... -
Unravelling the heterogeneity of soft tissue and bone sarcoma patients' health-related quality of life: a systematic literature review with focus on tumour location.
(ELSEVIER, 2020-01-01)Patients with sarcoma experience many physical and psychological symptoms, adversely affecting their health-related quality of life (HRQoL). HRQoL assessment is challenging due to the diversity of the disease. This review ... -
Unravelling the mechanisms of acquired immunomodulatory drug resistance in multiple myeloma
(Institute of Cancer Research (University Of London), 2023-12-01)Immunomodulatory drugs (IMiDs) are a cornerstone of multiple myeloma treatment and newer cereblon E3 ligase modulating drugs (CELMoDs) are in clinical trials. However, a major barrier to improving patient outcomes is ... -
Up-front cell-free DNA next generation sequencing improves target identification in UK first line advanced non-small cell lung cancer (NSCLC) patients.
(ELSEVIER SCI LTD, 2022-08-01)BACKGROUND: Genomic sequencing is necessary for first-line advanced non-small cell lung cancer (aNSCLC) treatment decision-making. Tissue next generation sequencing (NGS) is standard but tissue quantity, quality, and ... -
Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma.
(2020-08)Background The phase 3 JAVELIN Renal 101 trial (NCT02684006) demonstrated significantly improved progression-free survival (PFS) with first-line avelumab plus axitinib versus sunitinib in advanced renal cell carcinoma ... -
Updated recommendations regarding the management of older patients with breast cancer: a joint paper from the European Society of Breast Cancer Specialists (EUSOMA) and the International Society of Geriatric Oncology (SIOG).
(ELSEVIER SCIENCE INC, 2021-07-01)Breast cancer is increasingly prevalent in older adults and is a substantial part of routine oncology practice. However, management of breast cancer in this population is challenging because the disease is highly heterogeneous ... -
Updated Standardized Definitions for Efficacy End Points (STEEP) in Adjuvant Breast Cancer Clinical Trials: STEEP Version 2.0.
(LIPPINCOTT WILLIAMS & WILKINS, 2021-08-20)PURPOSE: The Standardized Definitions for Efficacy End Points (STEEP) criteria, established in 2007, provide standardized definitions of adjuvant breast cancer clinical trial end points. Given the evolution of breast cancer ... -
Updates in Prostate Cancer Research and Screening in Men at Genetically Higher Risk.
(SPRINGERNATURE, 2021-01-01)PURPOSE OF REVIEW: Prostate cancer (PrCa) is the most common cancer in men in the western world and is a major source of morbidity and mortality. Currently, general population PrCa screening is not recommended due to the ... -
Updates on radiotherapy-immunotherapy combinations: Proceedings of 6th annual ImmunoRad conference.
(TAYLOR & FRANCIS INC, 2023-12-31)Focal radiation therapy (RT) has attracted considerable attention as a combinatorial partner for immunotherapy (IT), largely reflecting a well-defined, predictable safety profile and at least some potential for immunostimulation. ... -
Upfront Docetaxel in the Post-STAMPEDE World: Lessons from an Early Evaluation of Non-trial Usage in Hormone-Sensitive Prostate Cancer.
(ELSEVIER SCIENCE LONDON, 2017-10-01) -
Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
(SPRINGERNATURE, 2023-03-16)Prostate cancer is the most common cancer in men and it is estimated that over 350,000 men worldwide die of prostate cancer every year. There remains an unmet clinical need to improve how clinically significant prostate ... -
Uridine-derived ribose fuels glucose-restricted pancreatic cancer.
(NATURE PORTFOLIO, 2023-06-01)Pancreatic ductal adenocarcinoma (PDA) is a lethal disease notoriously resistant to therapy1,2. This is mediated in part by a complex tumour microenvironment3, low vascularity4, and metabolic aberrations5,6. Although altered ... -
The Urine Biomarker PUR-4 Is Positively Associated with the Amount of Gleason 4 in Human Prostate Cancers.
(2021-11-03)The Prostate Urine Risk (PUR) biomarker is a four-group classifier for predicting outcome in patients prior to biopsy and for men on active surveillance. The four categories correspond to the probabilities of the presence ... -
Urine-derived lymphocytes as a non-invasive measure of the bladder tumor immune microenvironment.
(ROCKEFELLER UNIV PRESS, 2018-11-05)Despite the advances in cancer immunotherapy, only a fraction of patients with bladder cancer exhibit responses to checkpoint blockade, highlighting a need to better understand drug resistance and identify rational ... -
Urm1, not quite a ubiquitin-like modifier?
(SHARED SCIENCE PUBLISHERS OG, 2021-11-01)Ubiquitin related modifier 1 (Urm1) is a unique eukaryotic member of the ubiquitin-fold (UbF) protein family and conserved from yeast to humans. Urm1 is dual-functional, acting both as a sulfur carrier for thiolation of ... -
Urological referral of asymptomatic men in general practice in England
(NATURE PUBLISHING GROUP, 2008-04-01)The Prostate Cancer Risk Management Programme (PCRMP) launched in November 2002 provides guidelines for general practitioners (GPs) on age-specific prostate-specific antigen (PSA) cutoff levels in asymptomatic men. The ... -
US Backscatter for Liver Fat Quantification: An AIUM-RSNA QIBA Pulse-Echo Quantitative Ultrasound Initiative.
(RADIOLOGICAL SOC NORTH AMERICA (RSNA), 2022-12-01)Nonalcoholic fatty liver disease (NAFLD) is believed to affect one-third of American adults. Noninvasive methods that enable detection and monitoring of NAFLD have the potential for great public health benefits. Because ... -
Use of a Novel Nonparametric Version of DEPTH to Identify Genomic Regions Associated with Prostate Cancer Risk.
(AMER ASSOC CANCER RESEARCH, 2016-12-01)BACKGROUND: We have developed a genome-wide association study analysis method called DEPTH (DEPendency of association on the number of Top Hits) to identify genomic regions potentially associated with disease by considering ... -
Use of anastrozole for breast cancer prevention (IBIS-II): long-term results of a randomised controlled trial.
(2020-01)BACKGROUND:Two large clinical trials have shown a reduced rate of breast cancer development in high-risk women in the initial 5 years of follow-up after use of aromatase inhibitors (MAP.3 and International Breast Cancer ... -
Use of cyclin-dependent kinase 4/6 (CDK4/6) inhibitors in older patients with ER-positive HER2-negative breast cancer: Young International Society of Geriatric Oncology review paper.
(SAGE PUBLICATIONS LTD, 2018-11-20)The current standard of care for the management of estrogen receptor (ER)-positive and human epidermal growth factor receptor 2 (HER2)-negative breast cancer has been redefined by the introduction of cyclin-dependent kinase ...
